[PDF][PDF] Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial
G Witberg, I Kalka, R Kornowski, E Segal - practice, 2022 - researchgate.net
Aims The advantages of direct oral anticoagulants (DOACs) over warfarin are well
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
[HTML][HTML] Atraumatic Splenic Rupture: A Notable Complication of Rivaroxaban Use
CAO Perez, K Menchaca, CX Jones, EO Perez, S Isaac - Cureus, 2023 - ncbi.nlm.nih.gov
Direct oral anticoagulants (DOACs) are well known to be associated with bleeding
complications. However, little is known about their association with atraumatic splenic …
complications. However, little is known about their association with atraumatic splenic …
[PDF][PDF] Antithrombotic therap in the Netherlands: ne insights from nation ide data
Q Chen - Thromb Haemost, 2022 - scholarlypublications …
[5] Toorop MMA, Chen Q, Kruip M, van der Meer FJM, Nierman MC, Faber L, et al. Switching
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …
from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation …
Optimization for small volume of distribution leading to the discovery of apixaban
K He - Overcoming Obstacles in Drug Discovery and …, 2023 - Elsevier
Initial discovery efforts to improve on warfarin therapy in the 1990s led to several clinical and
preclinical development candidates at DuPont Pharmaceuticals Company, including the first …
preclinical development candidates at DuPont Pharmaceuticals Company, including the first …
Atraumatic Splenic Rupture: A Notable Complication of Rivaroxaban Use
K Menchaca, CX Jones, OP Erika, S Isaac - Cureus, 2023 - search.proquest.com
Direct oral anticoagulants (DOACs) are well known to be associated with bleeding
complications. However, little is known about their association with atraumatic splenic …
complications. However, little is known about their association with atraumatic splenic …
Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation based on Blood Coagulation Activity and Drug Plasma Concentration …
M Suwa, I Mori, M Kino, Y Matsui, M Yoshinaga… - 2024 - preprints.org
Background: The safety and effectiveness of factor-Xa (FXa) inhibitors for nonvalvular atrial
fibrillation (NVAF) remains inconclusive. We investigated the current dosing of rivaroxaban …
fibrillation (NVAF) remains inconclusive. We investigated the current dosing of rivaroxaban …
[PDF][PDF] Angiopathie amyloïde cérébrale et fibrillation atriale: le dilemme des anticoagulants Cerebral amyloid angiopathy and atrial fibrillation: anticoagulant dilemma
L Boutitie, M Verny, S Alamowitch… - … et psychologie & …, 2023 - hal.sorbonne-universite.fr
Résumé L'angiopathie amyloïde cérébrale et la fibrillation atriale sont deux pathologies
fréquentes chez le patient âgé, entrainant un dilemme thérapeutique: rapport bénéfice …
fréquentes chez le patient âgé, entrainant un dilemme thérapeutique: rapport bénéfice …
[PDF][PDF] Unraveling genetic contributors to bleeding events induced by rivaroxaban treatment
Y Chen, C Deng, L Miao, Z Zhuo… - Clinical and Translational …, 2023 - researchgate.net
Rivaroxaban, a non-vitamin K antagonist oral anticoagulant, is a potent inhibitor of factor-Xa
activity. As a direct oral anticoagulant (DOAC), it is commonly utilized for stroke prevention in …
activity. As a direct oral anticoagulant (DOAC), it is commonly utilized for stroke prevention in …
[PDF][PDF] Maxim Grymonprez1, Tine L. De Backer2, Xander Bertels1, Stephane Steurbaut3, 4 and Lies Lahousse1, 5
GL Kyriakopoulos, M Giner-Soriano, G i Gurina… - 2023 - academia.edu
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
Assessing the link between rivaroxaban concentration and the onset of renal impairment in elderly patients: A retrospective observational study
MU Rani, C Karuppiah… - Asian Journal of Medical …, 2024 - ajmsjournal.info
Background: Rivaroxaban is a widely used anticoagulant, but its impact on renal function,
particularly at varying plasma concentrations, remains a critical area of investigation. This …
particularly at varying plasma concentrations, remains a critical area of investigation. This …